Version 1
: Received: 18 December 2023 / Approved: 19 December 2023 / Online: 19 December 2023 (16:52:48 CET)
How to cite:
Nguyen, H.T.; Falzarano, D.; Gerdts, V.; Liu, Q. Construction and Immunogenicity of SARS-CoV-2 Virus-like Particle Expressed by Recombinant Baculovirus BacMam. Preprints2023, 2023121468. https://doi.org/10.20944/preprints202312.1468.v1
Nguyen, H.T.; Falzarano, D.; Gerdts, V.; Liu, Q. Construction and Immunogenicity of SARS-CoV-2 Virus-like Particle Expressed by Recombinant Baculovirus BacMam. Preprints 2023, 2023121468. https://doi.org/10.20944/preprints202312.1468.v1
Nguyen, H.T.; Falzarano, D.; Gerdts, V.; Liu, Q. Construction and Immunogenicity of SARS-CoV-2 Virus-like Particle Expressed by Recombinant Baculovirus BacMam. Preprints2023, 2023121468. https://doi.org/10.20944/preprints202312.1468.v1
APA Style
Nguyen, H.T., Falzarano, D., Gerdts, V., & Liu, Q. (2023). Construction and Immunogenicity of SARS-CoV-2 Virus-like Particle Expressed by Recombinant Baculovirus BacMam. Preprints. https://doi.org/10.20944/preprints202312.1468.v1
Chicago/Turabian Style
Nguyen, H.T., Volker Gerdts and Qiang Liu. 2023 "Construction and Immunogenicity of SARS-CoV-2 Virus-like Particle Expressed by Recombinant Baculovirus BacMam" Preprints. https://doi.org/10.20944/preprints202312.1468.v1
Abstract
The pandemic SARS-CoV-2 continues to evolve to give rise to variants of concern that can escape vaccine-induced immunity. As such, more effective vaccines are urgently needed. In this study, we evaluated virus-like particle (VLP) as a vaccine platform for SAS-CoV-2. The spike, envelope, and membrane proteins of the SARS-CoV-2 Wuhan strain were expressed by a single recombinant baculovirus BacMam and assembled into VLPs in cell culture. The morphology and size of the SARS-CoV-2 VLP as shown by transmission electron microscopy was found to be similar to the authentic SARS-CoV-2 virus particle. In a mouse trial, two intramuscular immunizations of the VLP BacMam with no adjuvant elicited spike-specific binding antibodies in both sera and bronchoalveolar lavage fluids. Importantly, BacMam VLP -vaccinated mouse sera showed neutralization activity against SARS-CoV-2 spike pseudotyped lentivirus. Our results indicated that the SARS-CoV-2 VLP BacMam stimulated spike-specific immune responses with neutralization activity.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
